A database of FDA approved therapeutic peptides and proteins
ID1022 | ThPPIDTh1003 | NameDornase alfa | Peptide SequenceLKIAAFNIQTFGETKMSNAT Full view | Length255 | Functional ClassificationIb | DiseaseMetabolic | BrandPulmozyme | CompanyGenentech Inc | Physical AppearanceN.A. | Route of AdministartionAdministered by inhalation of an aerosol mist produced by a compressed air driven nebulizer system | CategoryEnzymes | TargetDNA |
ID1023 | ThPPIDTh1003 | NameDornase alfa | Peptide SequenceLKIAAFNIQTFGETKMSNAT Full view | Length255 | Functional ClassificationIb | DiseaseMetabolic | BrandViscozyme | CompanyRoche (Chile) | Physical AppearanceN.A. | Route of AdministartionAdministered by inhalation of an aerosol mist produced by a compressed air driven nebulizer system | CategoryEnzymes | TargetDNA |
ID1049 | ThPPIDTh1008 | NamePeginterferon alfa-2a | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPegasys | CompanyHoffman-La Roche Inc | Physical AppearanceSterile, preservative-free, colorless to light yellow injectable solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1055 | ThPPIDTh1009 | NameAlteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandActivase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous | CategoryThrombolytic Agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1059 | ThPPIDTh1010 | NameInterferon alfa-n1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseInfectious /Immunological | BrandWellferon | CompanyGlaxoSmithKline | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntiviral Agents, Immunologic factors, Immunosuppressiv agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1064 | ThPPIDTh1011 | NameDarbepoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandAranesp | CompanyAmgen Inc | Physical AppearanceSterile, colorless, preservative-free solution containing polysorbate | Route of AdministartionIntravenousor Subcutaneous administration | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1067 | ThPPIDTh1012 | NameReteplase | Peptide SequenceSYQGNSDCYFGNGSAYRGTH Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandRetavase | CompanyCentocor | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryFibrinolytic Agents, Thrombolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1071 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandBinocrit | CompanySandoz | Physical AppearanceClear colourless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1072 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpocept | CompanyLupin pharma | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1073 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpofit | CompanyIntas pharma | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1074 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogen | CompanyAmgen Inc. | Physical AppearanceSterile, colorless liquid | Route of AdministartionSubcutaneous Injection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1075 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogin | CompanyChugai | Physical AppearanceN.A. | Route of AdministartionSubcutaneous or by Intravenous. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1076 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEprex | CompanyJanssen-Cilag. Ortho Biologics LLC | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1077 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandNanokine | CompanyNanogen Pharmaceutical biotechnology, Vietnam) | Physical AppearanceSterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1078 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandProcrit | CompanyOrtho Biotech | Physical AppearanceSterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Route of AdministartionIntravenous(IV) or Subcutaneous (SC) administration. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1098 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandCalcimar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1099 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandFortical | CompanyN.A. | Physical AppearanceNasal spray | Route of AdministartionIntranasal use | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1100 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandMiacalcin | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1110 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon | CompanyInterferon Sciences Inc. | Physical AppearanceSolution | Route of AdministartionInjection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1111 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon LDO | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1112 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon N Injection | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1117 | ThPPIDTh1016 | NamePegfilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandNeulasta | CompanyAmgen Inc. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-neutropenic agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase |
ID1120 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeucomax | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1121 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeukine | CompanyBerlex Laboratories Inc | Physical AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Route of AdministartionSubcutaneous Injection (SC) or Intravenous infusion (IV) | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1135 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPEG-Intron | CompanySchering Corp | Physical AppearancePowder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1136 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandUnitron PEG | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1210 | ThPPIDTh1028 | NameTenecteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandTNKase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
ID1215 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandMenopur | CompanyN.A. | Physical AppearanceSterile, lyophilized powder which is reconstitution with sterile 0.9% Sodium Chloride Injection. | Route of AdministartionSubcutaneous Injection | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1216 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandRepronex | CompanyN.A. | Physical AppearanceSterile, lyophilized form | Route of AdministartionSubcutaneous or Intramuscular Injection. | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1226 | ThPPIDTh1030 | NameInterferon gamma-1b | Peptide SequenceCYCQDPYVKEAENLKKYFNA Full view | Length146 | Functional ClassificationIb | DiseaseImmunological | BrandActimmune | CompanyInterMune Inc | Physical AppearanceSterile, clear, colorless solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon gamma receptor 1,Interferon gamma receptor 2 |
ID1229 | ThPPIDTh1031 | NameInterferon Alfa-2a, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandRoferon A | CompanyHoffmann-La Roche Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous Injection | CategoryN.A. | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1230 | ThPPIDTh1031 | NameInterferon Alfa-2a, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandVeldona | CompanyAmarillo Biosciences | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryN.A. | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1234 | ThPPIDTh1032 | NameCoagulation factor VIIa | Peptide SequenceANAFLEELRPGSLERECKEE Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandNovoSeven | CompanyNovo Nordisk | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionInjection | CategoryThrombotic Agents, Coagulants | TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
ID1242 | ThPPIDTh1033 | NameOprelvekin | Peptide SequenceGPPPGPPRVSPDPRAELDST Full view | Length177 | Functional ClassificationIb | DiseaseCancer/Haemetological | BrandNeumega | CompanyGenetics Institute Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionSubcutaneous injection | CategoryCoagulants and Thrombotic Agents, Anti-neoplastic agents | TargetInterleukin-11 receptor subunit alpha |
ID1246 | ThPPIDTh1034 | NamePalifermin | Peptide SequenceSYDYMEGGDIRVRRLFCRTQ Full view | Length140 | Functional ClassificationIb | DiseaseCancer | BrandKepivance | CompanyAmgen Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryAnti-Mucositis Agents | TargetFibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
ID1257 | ThPPIDTh1036 | NameAldesleukin | Peptide SequenceMAPTSSSTKKTQLQLEHLLL Full view | Length134 | Functional ClassificationIb | DiseaseCancer/Infectious | BrandProleukin | CompanyChiron Corp | Physical AppearanceSterile, white to off-white, lyophilized cake | Route of AdministartionIntravenous administration | CategoryAntineoplastic Agents, Anti-HIV agents | TargetInterleukin-2 receptor subunit beta,Interleukin-2 receptor subunit alpha,Cytokine receptor common subunit gamma |
ID1269 | ThPPIDTh1039 | NameLutropin alfa | Peptide SequenceAlpha Chain: APDVQDC Full view | Length213 | Functional ClassificationIb | DiseaseHormonal | BrandLuveris | CompanySerono | Physical AppearanceWhite lyophilised pellet withg clear colourless solvent to make solution | Route of AdministartionSubcutaneous (SC) administration | CategoryFertility Agents | TargetLutropin-choriogonadotropic hormone receptor |
ID1341 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandAvonex | CompanyBiogen Inc | Physical AppearanceLyophilized powder vial, Sterile liquid as single used prefilled syringe and also available as single use prefilled autoinjector. | Route of AdministartionIntramuscular Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1342 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1343 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaseron | CompanyMerck | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1344 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBlastoferon | CompanySidus | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1345 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1346 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandRebif | CompanyMerck | Physical AppearanceSterile solution in a prefilled syringe or REBIF Rebidose autoinjector | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1363 | ThPPIDTh1052 | NameEptifibatide | Peptide SequenceMpr-Har-Gly-Asp-Trp- Full view | Length7 | Functional ClassificationIb | DiseaseHematological/Metabolic | BrandINTEGRILIN | CompanySchering-Plough/Essex | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution of Eptifibatide | Route of AdministartionInjection Solution for IIntravenousUse | CategoryPlatelet Aggregation Inhibitors | TargetLutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
ID1372 | ThPPIDTh1055 | NameFollitropin beta | Peptide SequenceA Chain: APDVQDCPECT Full view | Length204 | Functional ClassificationIb | DiseaseHormonal disorders | BrandFollistim AQ | CompanyMerck | Physical AppearanceSterile aqueous solution | Route of AdministartionSubcutaneous or Intramuscular administration | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor |
ID1375 | ThPPIDTh1056 | NameVasopressin | Peptide SequenceCYFQNCPRG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitressin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, aqueous solution of synthetic vasopressin | Route of AdministartionIntramuscular or Subcutaneous use | CategoryAntidiuretic Agents | TargetVasopressin V2 receptor,Vasopressin V1a receptor,Vasopressin V1b receptor |
ID1376 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaseron | CompanyBayer | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1377 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1378 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1379 | ThPPIDTh1058 | NameInterferon alfacon-1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological/Infectious | BrandINFERGEN | CompanyKadmon Pharmaceuticals, LLC. | Physical AppearanceSterile, clear, colorless, preservative-free liquid | Route of AdministartionSubcutaneous Injection | CategoryAntiviral Agents and Immunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |